BioAge LabsBIOA
$5.6-1.8%11월 13일 종가 기준
시가총액 $0.3B
3달 전보다 -76.5%
최고 $24.89최저 $4.84
지켜보기 의견AI 점수 61 / 100
인체 노화 메커니즘을 표적해 대사질환을 치료하고 예방하는 신약을 개발해요.
We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. We focus on identifying biological pathways associated with longer, healthier human lifespans and developing pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases.
진행 중인 임상과 AI 예측
- Phase 2BGE-102 먹는 당뇨병성 황반부종 치료제 2상 임상모집 중A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema76%
- Phase 2BGE-102 비만 및 심혈관 위험군 2상 임상모집 중A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors47%
성공 확률은 BERA의 AI 모델(임상 설계·약물 구조·과거 사례 기반)이 계산한 값이에요. 실제 결과와 다를 수 있어요.